On 28 October 2005, orphan designation (EU/3/05/324) was granted by the European Commission to ACE Pharmaceuticals BV, The Netherlands, for levamisol hydrochloride for the treatment of nephrotic syndrome.
Treatment of nephrotic syndrome
|Orphan designation status||
|EU designation number||
|Date of designation||
ACE Pharmaceuticals BV
3891 ZK Zeewolde
Telephone: +31 36 522 72 01
Telefax: +31 36 522 9096
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: